Save Article

Biogen's Avonex Helps
Delay Multiple Sclerosis

Biogen Inc.'s popular Avonex drug, used to treat multiple sclerosis, has also proved its usefulness in delaying onset of the debilitating disease among those who show early signs of it.

Biogen stock rose more than 9% after the Cambridge, Mass., biotechnology company announced it had halted a 383-patient trial because an interim analysis by an independent monitoring panel found the drug to be effective in stalling disease.